Antigen-binding protein for hror1 and use thereof

By developing specific antigen binding proteins and bispecific antibodies, binding to the Ig-like and Kringle domains of ROR1, the difficulties and safety problems of existing targeted ROR1 drugs have been solved, and efficient binding and anti-tumor activity of ROR1 have been achieved. .

WO2024227426A1PCT designated stage expired Publication Date: 2024-11-07TAICHENGSI (SHANGHAI) BIOMEDICAL CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/090585
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-02-07
Filing Date
2024-04-29
Publication Date
2024-11-07

AI Technical Summary

Technical Problem

The existing targeted ROR1 drugs have not been clinically confirmed, and the high homology of the extracellular region of ROR1 leads to difficulties in antibody development. The existing ADC products have safety and drug resistance problems.

Method used

Developed antigen-binding proteins that specifically bind to hROR1, including antibodies and bispecific antibodies with specific variable region sequences, binding to Ig-like and Kringle domains, for the preparation of antibody-conjugated drugs targeting ROR1.

Benefits of technology

It achieved efficient binding and endocytosis activity on ROR1, with good anti-tumor activity, and provided new tumor treatment methods, especially anti-hROR1 ADCs, which demonstrated tumor inhibitory activity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024090585_07112024_PF_FP_ABST
    Figure CN2024090585_07112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to an antigen-binding protein for hROR1 and the use thereof, and particularly relates to an antigen-binding protein for hROR1, a bispecific antigen structured protein, a nucleic acid molecule encoding the antigen-binding protein, a vehicle, a cell, a drug molecule and the use thereof. Provided are different antibodies targeting the Ig-like domain or Kringle domain of hROR1 and bispecific antibodies based on these antibodies, and on this basis, compositions, such as ADCs combining different linkers and toxins, are produced. These antibodies and compositions provide new means for diagnosis and treatment of tumors. In particular, an anti-hROR1 ADC has a good anti-tumor activity and thus has a potential for use in tumor treatment.
Need to check novelty before this filing date? Find Prior Art

Description

hROR1 antigen binding protein and its use Technical Field

[0001] The present invention relates to an hROR1 antigen-binding protein, a bispecific antigen-binding protein, a nucleic acid molecule encoding the antigen-binding protein, a vector, a cell, a drug molecule, and uses thereof. Background Art

[0002] Receptor tyrosine kinase orphan receptor-1 (ROR1) and its family member, receptor tyrosine kinase orphan receptor-2 (ROR2), belong to the receptor tyrosine kinase (RTK) family and have recently attracted significant attention as tumor targets. ROR1 and ROR2 are structurally similar, both being type I transmembrane proteins. The mature, full-length proteins consist of an extracellular region comprised of three distinct domains (Ig-like, Frizzled, and Kringle), a transmembrane region, and an intracellular domain. The intracellular region contains a tyrosine kinase domain, two serine / threonine-rich domains, and a proline-rich domain. Both ROR1 and ROR2 are highly expressed in a variety of tumor tissues, but ROR2 is also expressed at low to moderate levels in some normal tissues. Although ROR1 can be detected in embryonic tissues, it is almost not expressed in normal adult tissues, except for very low levels of expression in the testis, uterus, lung, bladder and colon (Clin Cancer Res 2008; 14(2), doi:10.1158 / 1078-0432.CCR-07-1823), and is therefore considered a good tumor target.

[0003] ROR1 is widely expressed in both hematological tumors and solid tumors. For example, ROR1 is highly expressed in hematological tumors such as chronic lymphocytic leukemia (CLL), some acute lymphocytic leukemia (ALL), and chronic mantle cell lymphoma (CML). ROR1 is also highly expressed in a variety of solid tumors such as sarcoma, ovarian cancer, renal cell carcinoma, head and neck cancer, breast cancer, lung cancer, malignant mesothelioma, colon cancer, neuroblastoma, melanoma, and other tumor tissues. High ROR1 expression is associated with accelerated disease progression and poor prognosis in cancers such as CLL and ovarian cancer (Sci Rep. 2014 Jul 24; 4: 5811. doi: 10.1038 / srep05811; Blood. 2016 Dec 22; 128(25): 2931–2940. 10.1182 / blood-2016-04-712562). ROR1 may promote tumor development and progression by participating in multiple signal transduction pathways. Reports have shown that ROR1 may mediate Wnt5a, Wnt5b, and Wnt16 signaling, enhancing cell proliferation, inhibiting apoptosis, inducing epithelial-mesenchymal transition (EMT) and cancer cell migration and metastasis, and promoting pit formation and endocytosis (Cells 2021, 10, 142, doi: 10.3390 / cells10010142; Nat Commun 2016 Jan 4; 7: 10060. doi: 10.1038 / ncomms10060).

[0004] As previously mentioned, ROR1 is specifically expressed in tumors and may promote tumor growth. Therefore, ROR1 is considered a promising target for cancer therapy, and efforts have been underway to develop ROR1-specific antibodies. ROR1 shares high homology across mammalian species, with its extracellular domain amino acid sequence being identical between humans and cynomolgus macaques, 96.8% identical between humans and mice, and 96.6% identical between humans and rats. Consequently, generating high-affinity antibodies against this target through standard techniques, such as animal immunization, presents challenges.

[0005] Strategies targeting ROR1 mainly include monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and CAR-T. Currently, no products targeting ROR1 have been clinically confirmed. In addition, the extracellular region of ROR1 has three different domains. Among the three antibody-drug conjugates targeting ROR1 that have entered the clinical research stage, VLS-101 and NBE002 target the Ig-like domain, and LCB71 targets the Frizzled domain. Specific recognition of different domains or different epitopes in the same domain may result in different affinities, endocytosis efficiencies, or biological functions. In particular, bispecific antibodies composed of different antibodies that recognize different epitopes may increase the functional properties of the antibodies. In addition, existing ADC products have safety and drug resistance issues.

[0006] Summary of the Invention

[0007] The main purpose of the present invention is to provide an antigen binding protein that can specifically bind to hROR1 and has good antigen binding activity.

[0008] The first aspect of the present invention relates to an isolated antigen-binding protein capable of binding to hROR1, comprising any one of a to o:

[0009] a. having a first heavy chain variable region comprising a HCDR1 having an amino acid sequence of TYAMS, a HCDR2 having an amino acid sequence of SISSGGSTYYPDSVKG, and a HCDR3 having an amino acid sequence of YSLMVEAHWYFDV,

[0010] b. having a second heavy chain variable region comprising HCDR1 of the amino acid sequence SYAMS, HCDR2 of the amino acid sequence SISSGGSTYYPDSVKG, and HCDR3 of the amino acid sequence GYSNYVDWYFDV,

[0011] c. having a third heavy chain variable region comprising a HCDR1 having an amino acid sequence of DYTMH, a HCDR2 having an amino acid sequence of GIDPNYGGTNYNEKFKD, and a HCDR3 having an amino acid sequence of DDGYYEDYFDY,

[0012] d. having a fourth heavy chain variable region comprising a HCDR1 having an amino acid sequence of SYWIE, a HCDR2 having an amino acid sequence of EILPGSGNTQNNEKFKG, and a HCDR3 having an amino acid sequence of EGRRSHFFDY,

[0013] e. having a fifth heavy chain variable region comprising a HCDR1 of the amino acid sequence RYAMS, a HCDR2 of the amino acid sequence SISSGGSTYYPDSVKG, and a HCDR3 of the amino acid sequence GYYGNNDWYFDV,

[0014] f. having a first light chain variable region comprising LCDR1 having an amino acid sequence of KASQDINSYLS, LCDR2 having an amino acid sequence of RANRLVD, and LCDR3 having an amino acid sequence of LQYDEFPYT,

[0015] g. having a second light chain variable region comprising LCDR1 of the amino acid sequence KATQDINSYLS, LCDR2 of the amino acid sequence RPNRLVD, and LCDR3 of the amino acid sequence LQYDEFPYT,

[0016] h. having a third light chain variable region comprising LCDR1 of the amino acid sequence HASQGISSNIG, LCDR2 of the amino acid sequence HGTNLED, and LCDR3 of the amino acid sequence VQYAQFPYT,

[0017] i. having a fourth light chain variable region comprising LCDR1 of the amino acid sequence KSSQSLLNSSNQKNYLA, LCDR2 of the amino acid sequence FASTRES, and LCDR3 of the amino acid sequence QQHYSSPWT,

[0018] j. having a fifth light chain variable region comprising LCDR1 of the amino acid sequence KASQDINSYLS, LCDR2 of the amino acid sequence RANSLVD, and LCDR3 of the amino acid sequence LQFDEFPYT,

[0019] k. having the first heavy chain variable region described in item a and the first light chain variable region described in item f,

[0020] l. having the second heavy chain variable region described in item b and the second light chain variable region described in item g,

[0021] m. having the third heavy chain variable region described in item c and the third light chain variable region described in item h,

[0022] n. having a fourth heavy chain variable region as described in item d and a fourth light chain variable region as described in item i,

[0023] o. having the fifth heavy chain variable region described in item e and the fifth light chain variable region described in item j.

[0024] In some embodiments of the first aspect of the present invention, the framework region is of murine origin or human origin.

[0025] In some embodiments of the first aspect of the present invention, the framework region is an IgG framework region.

[0026] In some embodiments of the first aspect of the present invention, the human framework region has a back mutation at one or more sites relative to the murine framework region.

[0027] In some embodiments of the first aspect of the present invention, the present invention further comprises a constant region.

[0028] In some embodiments of the first aspect of the present invention, the constant region has a LALA mutation.

[0029] In some embodiments of the first aspect of the present invention, the heavy chain constant region of any one of a to e, k to o contains one or more mutations of C220S, A121C, V205C, K149C, D265C, S239C, A330C, and S442C.

[0030] In some embodiments of the first aspect of the invention, the CDR sequences are determined according to the Kabat definition scheme.

[0031] In some embodiments of the first aspect of the present invention, the antigen binding protein comprises an antibody or an antigen binding fragment thereof.

[0032] In some embodiments of the first aspect of the present invention, the antibody is selected from a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a humanized antibody or a fully human antibody.

[0033] In some embodiments of the first aspect of the present invention, the antigen-binding fragment is selected from a Fab antibody, a single-chain antibody or a single-domain antibody.

[0034] In some embodiments of the first aspect of the invention, the heavy chain variable region has a S62Q, S62A, S62N, S62E, S62V, S62Y, S62F or S62K mutation.

[0035] In some embodiments of the first aspect of the present invention, the light chain variable region has a G57A, G57S, G57N or G57L mutation.

[0036] In some embodiments of the first aspect of the present invention, the light chain variable region has a D56E, D56Q, D56T or D56Y mutation.

[0037] In some embodiments of the first aspect of the present invention, the light chain variable region has an S31A, S31Q, S31L, S31V, S31E, S31Y, S31F or S31K mutation.

[0038] In some embodiments of the first aspect of the present invention, the light chain variable region has a T57A, T57Q, T57L, T57V, T57E, T57Y, T57F or T57K mutation.

[0039] In some embodiments of the first aspect of the present invention, the light chain variable region has S27A, S27Q, S27L, S27V, S27E, S27Y, S27F, and S27K mutations.

[0040] In some embodiments of the first aspect of the invention, the heavy chain comprises an amino acid sequence as set forth in any one of SEQ ID Nos. 53, 54, 55, 56, 57, 58, 59, 60, 62, 63, 65, 73, 75, 78, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 90, 91, 92, 93, 134, or 135, and a light chain comprises an amino acid sequence as set forth in any one of SEQ ID Nos. 64, 66, 67, 68, 70, 71, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 105, 106, 108, 109, 110, 112, 113, 114, 115, 116, 117, 119, 120, 121, 122, or 123.

[0041] In some embodiments of the first aspect of the present invention, the antigen binding protein is selected from any one of antibodies Ab-1 to Ab-5, wherein:

[0042] Ab-1 has a heavy chain with an amino acid sequence as shown in SEQ ID NO.124, and a light chain with an amino acid sequence as shown in SEQ ID NO.129;

[0043] Ab-2 has a heavy chain having an amino acid sequence as shown in SEQ ID NO. 125, and a light chain having an amino acid sequence as shown in SEQ ID NO. 130;

[0044] Ab-3 has a heavy chain with an amino acid sequence as shown in SEQ ID NO. 126, and a light chain with an amino acid sequence as shown in SEQ ID NO. 131;

[0045] Ab-4 has a heavy chain with an amino acid sequence as shown in SEQ ID NO. 127, and a light chain with an amino acid sequence as shown in SEQ ID NO. 132;

[0046] Ab-5 has a heavy chain having an amino acid sequence as shown in SEQ ID NO.128, and a light chain having an amino acid sequence as shown in SEQ ID No.133.

[0047] A second aspect of the present invention relates to an isolated bispecific antigen binding protein capable of binding hROR1 having:

[0048] A first antigen-binding fragment that binds to the Ig-like domain of hROR1, wherein the first antigen-binding fragment has a first heavy chain variable region and a first light chain variable region, wherein

[0049] The first heavy chain variable region comprises a HCDR1 with an amino acid sequence of TYAMS, a HCDR2 with an amino acid sequence of SISSGGSTYYPDSVKG, and a HCDR3 with an amino acid sequence of YSLMVEAHWYFDV.

[0050] The first light chain variable region contains LCDR1 with an amino acid sequence of KASQDINSYLS, LCDR2 with an amino acid sequence of RANRLVD, and LCDR3 with an amino acid sequence of LQYDEFPYT.

[0051] A second antigen-binding fragment that binds to the Kringle domain of hROR1, wherein the second antigen-binding fragment has a fourth heavy chain variable region and a fourth light chain variable region, wherein

[0052] The fourth heavy chain variable region comprises a HCDR1 with an amino acid sequence of SYWIE, a HCDR2 with an amino acid sequence of EILPGSGNTQNNEKFKG, and a HCDR3 with an amino acid sequence of EGRRSHFFDY.

[0053] The four light chain variable regions contain LCDR1 with an amino acid sequence of KSSQSLLNSSNQKNYLA, LCDR2 with an amino acid sequence of FASTRES, and LCDR3 with an amino acid sequence of QQHYSSPWT.

[0054] In some embodiments of the second aspect of the present invention, the framework regions are of murine or human origin.

[0055] In some embodiments of the second aspect of the present invention, the framework region is an IgG framework region.

[0056] In some embodiments of the second aspect of the present invention, the human framework region has a back mutation at one or more sites relative to the mouse framework region.

[0057] In some embodiments of the second aspect of the present invention, a constant region is further included.

[0058] In some embodiments of the second aspect of the present invention, the constant region has a LALA mutation.

[0059] In some embodiments of the second aspect of the present invention, the heavy chain constant region of the first antigen-binding fragment contains one or more mutations of C220S, A121C, V205C, K149C, D265C, S239C, A330C, and S442C.

[0060] In some embodiments of the second aspect of the present invention, the heavy chain constant region of the second antigen-binding fragment contains one or more mutations of C220S, A121C, V205C, K149C, D265C, S239C, A330C, and S442C.

[0061] In some embodiments of the second aspect of the present invention, the bispecific antigen-binding protein is IgG-like or non-IgG-like.

[0062] In some embodiments of the second aspect of the present invention, the IgG-like antigen binding protein is selected from a DVD-Ig bispecific antigen binding protein, an IgG-scFv bispecific antigen binding protein, or a CrossMAb bispecific antigen binding protein.

[0063] In some embodiments of the second aspect of the present invention, any one of p, q, r, and s is present:

[0064] p. a first heavy chain having an amino acid sequence as shown in 61, a second heavy chain having an amino acid sequence as shown in 140, a first light chain having an amino acid sequence as shown in 69, and a second light chain having an amino acid sequence as shown in 141;

[0065] q. a first heavy chain having an amino acid sequence as shown in 72, a second heavy chain having an amino acid sequence as shown in 137, a first light chain having an amino acid sequence as shown in 69, and a second light chain having an amino acid sequence as shown in 141;

[0066] r. a first heavy chain having an amino acid sequence as shown in 89, a second heavy chain having an amino acid sequence as shown in 138, a first light chain having an amino acid sequence as shown in 69, and a second light chain having an amino acid sequence as shown in 139;

[0067] s. The first heavy chain has an amino acid sequence as shown in 136, and the second heavy chain has an amino acid sequence as shown in 142, the first light chain has an amino acid sequence as shown in 69, and the second light chain has an amino acid sequence as shown in 139.

[0068] In some embodiments of the second aspect of the present invention, the bispecific antigen-binding protein is selected from any one of antibodies Ab-6 to Ab-9, wherein Ab-6 is in the form of a DVD-Ig having a heavy chain with an amino acid sequence as shown in SEQ ID NO. 45 and a light chain with an amino acid sequence as shown in SEQ ID No. 49;

[0069] Ab-7 is in the form of IgG-scFv, having a heavy chain with the amino acid sequence shown in SEQ ID NO. 46, and a light chain with the amino acid sequence shown in SEQ ID No. 50;

[0070] Ab-8 is in the form of crossmab, having a first heavy chain with an amino acid sequence as shown in SEQ ID NO.47, and a first light chain with an amino acid sequence as shown in SEQ ID NO.67; a second heavy chain with an amino acid sequence as shown in SEQ ID NO.51, and a second light chain with an amino acid sequence as shown in SEQ ID NO.69;

[0071] Ab-9 is in the form of DVD-Ig, having a heavy chain with an amino acid sequence as shown in SEQ ID NO.48, and a light chain with an amino acid sequence as shown in SEQ ID No.52.

[0072] The third aspect of the present invention relates to a nucleic acid molecule encoding any of the above-mentioned antigen-binding proteins or any of the above-mentioned bispecific antigen-binding proteins.

[0073] The fourth aspect of the present invention relates to a vector, characterized in that it comprises the nucleic acid molecule described above.

[0074] The fifth aspect of the present invention relates to a cell comprising the nucleic acid molecule described above, and / or the vector described above.

[0075] The sixth aspect of the present invention relates to a drug molecule, characterized by comprising any of the above-mentioned antigen-binding proteins or any of the above-mentioned bispecific antigen-binding proteins.

[0076] In some embodiments of the sixth aspect of the present invention, a therapeutic agent or a detectable marker is further included, wherein the therapeutic agent is selected from a cytotoxic agent, a cytostatic agent, a radioactive isotope, an anti-angiogenic agent or a liposome.

[0077] In some embodiments of the sixth aspect of the present invention, the cytotoxic agent is derived from a plant, fungal or bacterial molecule or a derivative thereof.

[0078] In some embodiments of the sixth aspect of the present invention, the cytotoxic agent is selected from a peptide toxin, a protein toxin, or an alkylating toxin.

[0079] In some embodiments of the sixth aspect of the present invention, the cytotoxic agent is selected from one or more of maytansine alkaloids, auristatins, eribulin, taxanes, calicheamicin, cemadin, pyrrolobenzodiazepines, anthracyclines, camptothecin derivatives, α-amanitin and its derivatives, trabectedin and its derivatives, and rubectedin and its derivatives.

[0080] In some embodiments of the sixth aspect of the present invention, the therapeutic agent or detectable marker is coupled to the antigen binding protein via a cleavable or non-cleavable linker.

[0081] In some embodiments of the sixth aspect of the present invention, the linker has one or more linkers.

[0082] In some embodiments of the sixth aspect of the present invention, the linker is selected from one or more of an oligopeptide linker, a hydrazine linker, a thiourea linker, a triggered self-degradation linker, a succinimidyl trans-4-(maleimidomethyl)cyclohexane-1-carboxylate linker, a maleimide linker, a disulfide linker, a thioether linker, and an olefin linker.

[0083] In some embodiments of the sixth aspect of the present invention, the structure is as shown in Formula I:

[0084] Ab is the antigen binding protein, L is a linker containing one or more linkers, D is the therapeutic agent or detectable marker, and n is an integer selected from 1-20.

[0085] In some embodiments of the sixth aspect of the present invention, n is selected from integers ranging from 2 to 8.

[0086] The seventh aspect of the present invention relates to a pharmaceutical composition comprising any of the above-mentioned antigen-binding proteins, any of the above-mentioned bispecific antigen-binding proteins, the above-mentioned nucleic acid molecules, the above-mentioned vectors, the above-mentioned cells, and / or any of the above-mentioned drug molecules, and pharmaceutically acceptable carriers and / or additives.

[0087] The eighth aspect of the present invention relates to the use of any of the above-mentioned antigen-binding proteins, any of the above-mentioned bispecific antigen-binding proteins, any of the above-mentioned vectors, any of the above-mentioned cells, and / or any of the above-mentioned drug molecules in the preparation of drugs, wherein the drugs are used to diagnose, prevent and / or treat hROR1-related diseases and / or conditions.

[0088] In some embodiments of the eighth aspect of the present invention, the disease and / or condition comprises a tumor.

[0089] In some embodiments of the eighth aspect of the present invention, the tumor is chronic lymphocytic leukemia, acute lymphocytic leukemia, chronic mantle cell lymphoma, sarcoma, ovarian cancer, renal cell carcinoma, head and neck cancer, breast cancer, lung cancer, malignant mesothelioma, colon cancer, neuroblastoma or melanoma.

[0090] The present invention provides novel antibodies targeting the Ig-like and Kringle domains of hROR1, as well as bispecific antibodies based on these antibodies. Combinations of these antibodies are also available, such as ADCs combining different linkers and toxins. These antibodies and compositions provide new approaches for the diagnosis and treatment of tumors. In particular, anti-hROR1 ADCs exhibit excellent anti-tumor activity and have potential for tumor treatment. BRIEF DESCRIPTION OF THE DRAWINGS

[0091] FIG1 shows the extracellular regions of human ROR1 (hROR1) and human ROR2 (hROR2), including a signal peptide, an Ig-like domain, a Frizzled domain, and a Kringle domain.

[0092] Figure 2 shows the amino acid sequences of the variable immunoglobulin heavy and light chains of the novel murine anti-hROR1 mAbs.

[0093] Figure 3 shows the binding activity of chimeric mouse / human anti-hROR1 antibodies to the commercial mature hROR1 full-length extracellular region, three different hROR1 extracellular domains, and the mature hROR2 full-length extracellular region, as measured in Example 4. Ab1 has a high affinity for the hROR1 Ig-like domain, while Ab4, unlike the other antibodies, binds to the Kringle domain instead of the Ig-like domain, indicating that it recognizes a unique antigenic epitope.

[0094] FIG4 shows FACS cell staining of human triple-negative breast cancer cells MDA-MB-231 using anti-human ROR1 antibodies Ab-1, Ab-2, Ab-3, Ab-4, and Ab-5 as described in Example 4.

[0095] FIG5 shows the binding activity of selected chimeric murine / human IgGs to endogenous hROR1 expressed on human breast cancer cells MDA-MB-231, measured by fluorescence activated cell sorting (FACS).

[0096] Figure 6 shows the endocytosis of selected chimeric murine / human IgGs in human ovarian cancer cells PA-1 and human breast cancer cells MDA-MB-231 expressing endogenous hROR1. (A) Endocytosis activity of selected antibodies in PA-1 cells. (B) Endocytosis activity of selected antibodies in MDA-MB-231 cells. The selected antibodies exhibited significant endocytosis activity in both cell lines.

[0097] Figure 7 (A) shows schematic diagrams of the structures of different bispecific antibodies based on selected chimeric mouse / human IgG. (B) Lists the full-length sequences of these antibodies.

[0098] FIG8 shows the binding activity of selected bispecific antibodies to endogenous hROR1 expressed on human breast cancer cells MDA-MB-231.

[0099] Figure 9 shows the binding activity of chimeric antibody mutants or humanized anti-hROR1 antibodies to the full-length extracellular region of mature hROR1. The partially humanized antibody exhibited higher binding activity than the chimeric antibody.

[0100] Figure 10(A) schematically illustrates how to generate ADCs disclosed herein that are conjugated to different linker-payloads using cysteine ​​residues corresponding to antibody interchain disulfide bonds. Figure 10(B) schematically illustrates the main flow chart for generating ADCs using allene conjugation technology. Figure 10(C) schematically illustrates how to generate site-specifically conjugated ADCs disclosed herein based on introduced cysteine ​​mutations. Site-specifically conjugated ADCs are generated by introducing cysteine ​​mutations at selected sites through point mutagenesis and recombinant antibody expression.

[0101] Figure 11 (AC) shows the cytotoxicity of selected anti-ROR1 ADCs in the concentration range of 0.01 to 1000 nM on human triple-negative breast cancer cells MDA-MB-231. (D) shows the cytotoxicity of selected anti-ROR1 ADCs in the concentration range of 0.01 to 1000 nM on human sarcoma cells Saos2. (E) shows the cytotoxicity of selected anti-ROR1 ADCs in the concentration range of 0.01 to 1000 nM on human soft tissue sarcoma cells SK-UT-1.

[0102] Figure 12 shows the efficacy of ADC41, DAR4 in a xenograft model in female NCG mice injected with hROR1 positive MDA-MB-231 cells. The selected ADCs exhibited strong tumor inhibitory activity. DETAILED DESCRIPTION

[0103] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. In the event of a conflict, the descriptions and definitions herein shall prevail.

[0104] In view of the problems existing in the prior art, the present invention provides an antigen-binding protein that can specifically bind to hROR1 and has good antigen-binding activity. The antigen-binding protein of the present invention contains any one of a to o:

[0105] a. having a first heavy chain variable region comprising a HCDR1 having an amino acid sequence of TYAMS, a HCDR2 having an amino acid sequence of SISSGGSTYYPDSVKG, and a HCDR3 having an amino acid sequence of YSLMVEAHWYFDV,

[0106] b. having a second heavy chain variable region comprising HCDR1 of the amino acid sequence SYAMS, HCDR2 of the amino acid sequence SISSGGSTYYPDSVKG, and HCDR3 of the amino acid sequence GYSNYVDWYFDV,

[0107] c. having a third heavy chain variable region comprising a HCDR1 having an amino acid sequence of DYTMH, a HCDR2 having an amino acid sequence of GIDPNYGGTNYNEKFKD, and a HCDR3 having an amino acid sequence of DDGYYEDYFDY,

[0108] d. having a fourth heavy chain variable region comprising a HCDR1 having an amino acid sequence of SYWIE, a HCDR2 having an amino acid sequence of EILPGSGNTQNNEKFKG, and a HCDR3 having an amino acid sequence of EGRRSHFFDY,

[0109] e. having a fifth heavy chain variable region comprising a HCDR1 of the amino acid sequence RYAMS, a HCDR2 of the amino acid sequence SISSGGSTYYPDSVKG, and a HCDR3 of the amino acid sequence GYYGNNDWYFDV,

[0110] f. having a first light chain variable region comprising LCDR1 having an amino acid sequence of KASQDINSYLS, LCDR2 having an amino acid sequence of RANRLVD, and LCDR3 having an amino acid sequence of LQYDEFPYT,

[0111] g. having a second light chain variable region comprising LCDR1 of the amino acid sequence KATQDINSYLS, LCDR2 of the amino acid sequence RPNRLVD, and LCDR3 of the amino acid sequence LQYDEFPYT,

[0112] h. having a third light chain variable region comprising LCDR1 of the amino acid sequence HASQGISSNIG, LCDR2 of the amino acid sequence HGTNLED, and LCDR3 of the amino acid sequence VQYAQFPYT,

[0113] i. having a fourth light chain variable region comprising LCDR1 of the amino acid sequence KSSQSLLNSSNQKNYLA, LCDR2 of the amino acid sequence FASTRES, and LCDR3 of the amino acid sequence QQHYSSPWT,

[0114] j. having a fifth light chain variable region comprising LCDR1 of the amino acid sequence KASQDINSYLS, LCDR2 of the amino acid sequence RANSLVD, and LCDR3 of the amino acid sequence LQFDEFPYT,

[0115] k. having the first heavy chain variable region described in item a and the first light chain variable region described in item f,

[0116] l. having the second heavy chain variable region described in item b and the second light chain variable region described in item g,

[0117] m. having the third heavy chain variable region described in item c and the third light chain variable region described in item h,

[0118] n. having a fourth heavy chain variable region as described in item d and a fourth light chain variable region as described in item i,

[0119] o. having the fifth heavy chain variable region described in item e and the fifth light chain variable region described in item j. Types of hROR1 antigen-binding proteins of the present invention include, but are not limited to, full-length antibodies, antibody fragments, immunoconjugates, antibody analogs, antibody derivatives, fusion proteins, and the like. Antibodies include, but are not limited to, chimeric antibodies and humanized antibodies. Antibody fragments include, but are not limited to, Fab, Fab', F(ab)2, Fv, scFv, dsFv, VHH, and the like.

[0120] Chimeric antibodies generally refer to antibodies that have the V region (variable region) of a mouse monoclonal antibody and the C region (constant region) of a human immunoglobulin.

[0121] Humanized antibodies generally refer to antibodies formed by introducing the CDR sequences of mouse antibodies into the framework sequences of human VH and VL domains, respectively.

[0122] Hybridomas producing monoclonal antibodies to hROR1 of the present invention can be produced using known techniques. For example, first, hROR1 protein, cells expressing hROR1, or a gene encoding hROR1 are used as sensitizing antigens and immunized according to conventional immunization methods. Immune cells obtained from the immunized material are fused with known parent cells using conventional cell fusion methods to produce hybridomas. Furthermore, cells producing the target antibody are screened from these hybridomas using conventional screening methods, thereby selecting hybridomas that produce anti-hROR1 antibodies.

[0123] Specifically, the production of monoclonal antibodies can be carried out, for example, as follows. First, by expressing the hROR1 gene, hROR1 protein can be obtained and used as a sensitizing antigen for obtaining antibodies. That is, the gene sequence encoding hROR1 is enclosed in a known expression vector, and after transforming appropriate host cells, the target human hROR1 protein can be purified from these host cells or from the culture supernatant using known methods. Alternatively, purified natural hROR1 protein can also be used. Production can be achieved by combining or using a variety of chromatography methods such as conventional ion chromatography or affinity chromatography, one or more times. In addition, fusion proteins can also be used as immunogens. The fusion protein is obtained by fusing a desired partial polypeptide of the hROR1 protein with a different polypeptide. To prepare a fusion protein as an immunogen, for example, an antibody Fc fragment or a peptide tag can be used. A vector expressing a fusion protein can be produced by in-frame fusing genes encoding two or more desired polypeptide fragments and incorporating the fusion gene into an expression vector as described above.

[0124] The hROR1 protein purified as described above can be used as a sensitizing antigen for immunization of mammals. Alternatively, a partial peptide of hROR1 can also be used as a sensitizing antigen.

[0125] There are no particular limitations on the mammals to be immunized with the sensitizing antigen. To obtain monoclonal antibodies by cell fusion, it is preferred to select an immunized animal, taking into account compatibility with the parental cells used in cell fusion. Generally, rodents are preferred as immunized animals. Specifically, mice, rats, hamsters, or rabbits can be used as immunized animals. Additionally, monkeys and the like can also be used as immunized animals.

[0126] The above-mentioned animals can be immunized with sensitizing antigens according to known methods. For example, as a general method, mammals can be immunized by intraperitoneal or subcutaneous injection of sensitizing antigens. Specifically, the sensitizing antigen is administered to the mammal multiple times at intervals of 4 to 21 days. The sensitizing antigen can be diluted with PBS (Phosphate-Buffered Saline) or physiological saline at an appropriate rate for immunization. In addition, the sensitizing antigen can be administered together with an adjuvant. For example, it can be mixed and emulsified with Freund's complete adjuvant to form a sensitizing antigen. In addition, an appropriate carrier can be used for immunization with the sensitizing antigen. In particular, when a partial peptide with a small molecular weight is used as the sensitizing antigen, it is preferred that the sensitizing antigen peptide be bound to a carrier protein such as albumin or keyhole limpet hemocyanin for immunization.

[0127] After the mammal is immunized as described above and the desired antibody level in the serum is confirmed to be elevated, immune cells are collected from the mammal and cell fusion is performed. Spleen cells are particularly preferably used as the immune cells.

[0128] The screening and monocloning of the target antibody are preferably carried out using a screening method based on a well-known antigen-antibody reaction. For example, the antigen is bound to a carrier such as a small ball made of polystyrene or a commercially available 96-well microtiter plate, and reacted with the culture supernatant of the hybridoma. Then, after washing the carrier, an enzyme-labeled secondary antibody is reacted. If the culture supernatant contains a target antibody that reacts with the sensitizing antigen, the secondary antibody is bound to the carrier through this antibody. Finally, by detecting the secondary antibody bound to the carrier, it is possible to determine whether the target antibody is present in the culture supernatant. A hybridoma that produces the desired antibody with antigen binding ability can be cloned by a limiting dilution method or the like. At this time, as an antigen, a protein used for immunization and a substantially identical hROR1 protein can be preferably used. For example, an oligopeptide comprising the extracellular domain of hROR1 or a partial amino acid sequence constituting the region can be used as an antigen.

[0129] Chimeric and humanized antibodies can be produced using known methods. For example, a V region gene containing three CDRs and four FRs is amplified in its entirety using primers that are annealed at the 5' and 3' ends and attached with appropriate restriction enzyme recognition sequences. The DNA obtained as described above is assembled into an expression vector with DNA encoding a human antibody C region for in-frame fusion. This recombinant vector is introduced into a host to establish recombinant cells, which are then cultured to express the antibody-encoding DNA to produce the antibody. For details, see Example 2.

[0130] The antibody formats include, but are not limited to, IgG, IgM, IgA, IgE, and IgD, with IgG being preferred. Furthermore, the IgG includes IgG1, IgG2, IgG3, and IgG4. The constant regions used in chimeric and humanized antibodies include Cγ1, Cγ2, Cγ3, Cγ4, Cμ, Cδ, Cα1, Cα2, and Cε for heavy chains, and Cκ, Cλ, and other light chains.

[0131] LALA mutations can be introduced into the Fc region of the antibody to reduce the binding of the antibody to Fcγ receptors and complement. Mutations in the heavy chain constant region include, but are not limited to, one or more mutations of C220S, A121C, V205C, K149C, D265C, S239C, A330C, and S442C.

[0132] In the present invention, CDR is used to represent the complementary determining region (or hypervariable loop) of an antibody. The amino acid sequence in the CDR determines the chemical structure and characteristics of the antibody antigen binding site. The CDR in the heavy chain variable region (VH) is represented by HCDR, and the three heavy chain CDR regions are named HCDR1, HCDR2 and HCDR3 respectively; the CDR in the light chain variable region (VL) is represented by LCDR, and the three light chain CDR regions are named LCDR1, LCDR2 and LCDR3 respectively. It should be noted that the CDR region in the antibody is generally predicted and identified by experiments. Unless otherwise specified, the CDR sequences in the present invention are defined by the Kabat definition scheme, and the relevant amino acid numbering is determined by the Kabat numbering scheme. It should be understood that when different definition schemes are used to define CDR, the predicted CDR region sequences may only partially overlap, or be shortened or lengthened.

[0133] In antibody preparation, the CDR and FR gene sequences defined individually can be concatenated and amplified to full length using known methods according to different definition schemes, thereby further preparing various antibodies or antibody fragments.

[0134] The antibody fragment Fab refers to the VH region of the heavy chain variable region, the CH1 functional region of the first constant region of the heavy chain, and the entire light chain connected by disulfide bonds, which mainly plays the antigen binding function of the antibody.

[0135] scFv is a single-chain antibody. Specifically, it refers to an antibody in which the light chain variable region gene and the heavy chain variable region gene are connected at the DNA level with a suitable oligonucleotide chain (linker), so that they are expressed in the form of a single peptide chain in a suitable organism and folded into a new antibody consisting only of the heavy chain and light chain variable regions. There are no special restrictions on the linker. For example, any single-chain peptide containing about 3 to 25 residues can be used as a connector.

[0136] dsFv is a disulfide-stabilized antibody, specifically an antibody formed by mutating an amino acid residue in the heavy chain variable region (VH) and light chain variable region (VL) of the antibody to cysteine, and then linking VH and VL through interchain disulfide bonds.

[0137] VHH is a heavy chain single-domain antibody, specifically a small molecule antibody that contains only the VH functional domain but not the VL functional domain.

[0138] Fusion protein refers to the product of fusing antibody molecule fragments with other proteins (such as antibody enzymes, immunotoxins, immune cytokines, immunoadhesins, etc.) using genetic engineering technology.

[0139] Methods for preparing the various antibody fragments described above are known. One method involves enzymatic treatment of antibodies to produce antibody fragments. Enzymes used to produce antibody fragments include, but are not limited to, papain, pepsin, or plasmin. Another method involves constructing a gene encoding the antibody fragment, introducing the gene into an expression vector, and expressing the gene in an appropriate host cell to produce the antibody fragment.

[0140] The antibody derivatives of the present invention refer to products obtained by substituting, mutating, modifying, replacing, deleting and / or adding one or more amino acid residues in the antibodies of the present invention while retaining the endogenous function.

[0141] In the present invention, CH is used to represent the heavy chain constant region of an antibody, and CL is used to represent the light chain constant region of an antibody. The heavy chain constant region generally further includes the CH1, CH2, and CH3 domains. FR is used to represent the framework of an antibody variable region. The framework region of the heavy chain variable region is represented by HFR, and the four heavy chain framework regions are named HFR1, HFR2, HFR3, and HFR4 respectively; the framework region of the light chain variable region is represented by LFR, and the four light chain framework regions are named LFR1, LFR2, LFR3, and LFR4 respectively.

[0142] The heavy chain variable region has an S62Q, S62A, S62N, S62E, S62V, S62Y, S62F or S62K mutation.

[0143] The light chain variable region has a G57A, G57S, G57N or G57L mutation.

[0144] The light chain variable region has a D56E, D56Q, D56T or D56Y mutation.

[0145] The light chain variable region has an S31A, S31Q, S31L, S31V, S31E, S31Y, S31F or S31K mutation.

[0146] The light chain variable region has a T57A, T57Q, T57L, T57V, T57E, T57Y, T57F or T57K mutation.

[0147] The light chain variable region has S27A, S27Q, S27L, S27V, S27E, S27Y, S27F, and S27K mutations.

[0148] The present invention also relates to a bispecific antigen-binding protein capable of binding to HROR1, comprising a first antigen-binding fragment that binds to the Ig-like domain of hROR1 and a second antigen-binding fragment that binds to the Kringle domain.

[0149] The first antigen-binding fragment comprises a first heavy chain variable region and a first light chain variable region, wherein:

[0150] The first heavy chain variable region comprises a HCDR1 with an amino acid sequence of TYAMS, a HCDR2 with an amino acid sequence of SISSGGSTYYPDSVKG, and a HCDR3 with an amino acid sequence of YSLMVEAHWYFDV.

[0151] The first light chain variable region contains LCDR1 with an amino acid sequence of KASQDINSYLS, LCDR2 with an amino acid sequence of RANRLVD, and LCDR3 with an amino acid sequence of LQYDEFPYT.

[0152] The second antigen-binding fragment has a fourth heavy chain variable region and a fourth light chain variable region, wherein

[0153] The fourth heavy chain variable region comprises a HCDR1 with an amino acid sequence of SYWIE, a HCDR2 with an amino acid sequence of EILPGSGNTQNNEKFKG, and a HCDR3 with an amino acid sequence of EGRRSHFFDY.

[0154] The fourth light chain variable region contains LCDR1 with an amino acid sequence of KSSQSLLNSSNQKNYLA, LCDR2 with an amino acid sequence of FASTRES, and LCDR3 with an amino acid sequence of QQHYSSPWT.

[0155] Bispecific antibodies are divided into IgG-like bispecific antibodies containing Fc fragments and non-IgG-like antibodies without Fc fragments according to whether the Fc fragment is present. Non-IgG-like antibodies include BiTE bispecific antibodies, DART bispecific antibodies, TandAb bispecific antibodies, and Bi-Nanobody bispecific antibodies. Ig-like bispecific antibodies include Triomab quadroma bispecific antibodies, KIH IgG bispecific antibodies, CrossMAb bispecific antibodies, Orthodox-Fab IgG bispecific antibodies, YBODY bispecific antibodies, Two-in-One bispecific antibodies, DVD-Ig bispecific antibodies, IgG-ScFv and ScFv2-Fc bispecific antibodies, FIT-Ig bispecific antibodies, and Mebs-Ig bispecific antibodies. In this application, the binding activity of the prepared antigen-binding protein is detected using existing methods, such as flow cytometry. For example, the method of Example 4 can be used for detection.

[0156] The endocytic activity of the prepared antigen-binding proteins herein can be assayed using methods known to those skilled in the art. For example, a test antigen-binding protein containing a detectable marker can be incubated with cells expressing hROR1, and the fluorescence intensity of the protein upon entry into the cells can be measured by flow cytometry to analyze endocytic activity. See Example 5 for details.

[0157] The vectors of the present invention are used for the replication, transcription and / or translation of DNA or RNA. By cultivating cells containing the vectors, desired expression products can be produced. The selected vectors are known, such as plasmids.

[0158] In addition, the present invention also relates to a drug molecule containing the above antigen-binding protein or bispecific antigen-binding protein.

[0159] The drug molecule may also contain a therapeutic agent or a detectable marker.

[0160] The drug molecule may comprise any known drug form, including but not limited to proteins, peptides, small molecule drugs, antibody-drug conjugates, or combinations of various drug forms.

[0161] The antibody-drug conjugates in the present invention refer to antigen-binding proteins (usually antibodies or antibody fragments) coupled to therapeutic agents via a linker. Methods for preparing antibody-drug conjugates are known. Among them, the connection between the linker and the drug is usually produced by known chemical synthesis methods to form a linker-therapeutic agent structure that can be bound to the antibody. During the preparation of the antibody-drug conjugates, the antibody is coupled to one or more linker-therapeutic agent structures, and the coupling of the antibody and the linker-therapeutic agent structure is usually established for the side chains of lysine or cysteine ​​residues in the antibody. Among them, for the conjugation of lysine, the linker usually has N-hydroxysuccinimide, which can react with the ε-amino group of the lysine to form a stable amide bond to form a coupling of the antibody and the therapeutic agent. For the conjugation of cysteine, the linker usually has a functional group that can mediate the coupling reaction, such as a maleimide functional group, allenamide, etc., and the cysteine ​​is reduced to a disulfide bond by a known method to produce a reactive thiol, thereby conjugating with maleimide to form a coupling of the antibody and the therapeutic agent. For example, reference may be made to the method exemplified in Example 8 of the present invention.

[0162] Adoptable linkers include non-cleavable and cleavable ones. The linker may have one or more linkers, including but not limited to oligopeptide linkers (including cleavable and / or non-cleavable oligopeptide linkers), hydrazine linkers, thiourea linkers, triggered self-degradation (self-immolative) linkers, succinimidyl trans-4-(maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linkers, maleimide linkers, disulfide linkers, thioether linkers and / or olefin linkers.

[0163] The therapeutic agent that can be used can be an immunomodulator, such as Sting agonist, TLR7, TLR8 and / or TLR9 agonist, PD-1 inhibitor, etc.

[0164] Adoptable therapeutic agent can be cytotoxic agent, cytostatic agent etc.Cytotoxic agent can be molecule or its derivative from plant, fungus or bacterium, including but not limited to peptide toxin, protein toxin, alkylating agent toxin or other type toxin.Drug toxic agent can be selected from maytansine alkaloids (for example, maytansinol (maytansinol) or DM1 maytansine), auristatins (for example, monomethyl auristatin E or monomethyl auristatin F), eribulin, taxane, calicheamicin, cemadidine, pyrrolobenzodiazepine, anthracycline, camptothecin derivatives, α-amanitin and its derivatives, trabectedin and its derivatives, rubectedin and its derivatives One or more.The cytotoxic substance used in the present invention can be one, or two or more cytotoxic substances can be combined for use.

[0165] The therapeutic agent that can be used can also be a metabolite (for example, an antifolate such as methotrexate, a fluoropyrimidine such as 5-fluorouracil, cytarabine, or an analog of purine or adenosine); an intercalating agent (for example, an anthracycline such as doxorubicin, nemorubicin, or preferably a derivative of PNU-159682), daunorubicin, epirubicin, idarubicin, mitomycin-C, actinomycin D, or mithramycin, or other intercalating agents such as pyrrolobenzodiazepines; DNA-reactive agents such as calicheamicin, tiancimycins and other enediynes; platinum derivatives (for example, cisplatin or carboplatin); alkylating agents.

[0014] The therapeutic agent may be an anti-inflammatory agent (e.g., mechlorethamine, melphalan, chlorambucil, busulfan, cyclophosphamide, ifosfamide nitrosourea, or thiotepa); an RNA polymerase inhibitor such as α-amanitin; an anti-mitotic agent (e.g., a vinca alkaloid such as vincristine, or a taxane such as paclitaxel or docetaxel); a topoisomerase inhibitor (e.g., etoposide, teniposide, amsacrine, topotecan, exitecan); a cell cycle inhibitor (e.g., flavopyridol); or an anti-microtubule agent (e.g., epothilone, tubulysine, pre-tubulysine, a picrotoxin analog, or a calendula analog). The therapeutic agent may be a proteasome inhibitor or a topoisomerase inhibitor such as bortezomib, amsacrine, etoposide, etoposide phosphate, teniposide, or doxorubicin. Therapeutic radioisotopes include iodine (131I), yttrium (90Y), lutetium (177Lu), actinium (225Ac), praseodymium, astatine (At), rhenium (Re), bismuth (Bi or Bi) and rhodium (Rh). Antiangiogenic agents include linoamide, bevacizumab, angiostatin and razoxane.

[0166] Drug molecules containing detectable markers can be used for diagnosis. Such as contrast agents can be included. Contrast agents can be radioisotope labels such as iodine (131I or 125I), indium (111In), technetium (99Tc), phosphorus (32P), carbon (14C), tritium (3H), other radioisotopes (such as radioactive ions), or therapeutic radioisotopes such as one of the therapeutic radioisotopes listed above. In addition, contrast agents can include radiopaque materials, magnetic resonance imaging (MRI) agents, ultrasonic imaging agents and any other contrast agents suitable for detection by the device of imaging animal body. The detectable marker can also be a fluorescent marker, a biologically active enzyme marker, a luminescent marker or a chromophore marker.

[0167] The structure of the drug molecule is shown in Formula I:

[0168] Ab is the antigen binding protein, L is a linker comprising one or more linkers, D is the therapeutic agent or detectable marker, and n is an integer selected from 1 to 20. Further, it can be an integer from 2 to 8.

[0169] The pharmaceutical composition of the present invention can be administered orally or parenterally. Parenteral administration methods include injection, nasal administration, pulmonary administration, transdermal administration, and the like. Injection administration can further include intravenous injection, intramuscular injection, intraperitoneal injection, subcutaneous injection, and the like. In addition, the dosage can be specifically adjusted considering the patient's age and symptoms. As for the dosage, for example, the dosage can be 0.0001 mg to 1000 mg per kg of body weight per administration. For another example, each administration for each patient is 0.001 mg to 100,000 mg. It should be noted that the above dosage is only for illustration and is not intended to limit the range of the dosage.

[0170] The pharmaceutical composition of the present invention can be formulated according to a common method, and can also contain a pharmaceutically acceptable drug carrier and / or additive at the same time. For example, surfactants, excipients, colorants, spices, preservatives, stabilizers, buffers, suspending agents, isotonic agents, adhesives, disintegrants, lubricants, flow promoters, flavoring agents, etc. can be enumerated. In addition, it is not limited to this, and other commonly used drug carriers can be appropriately used. Specifically, as drug carriers, include but are not limited to light anhydrous silicic acid, lactose, crystalline cellulose, mannitol, starch, carboxymethylcellulose calcium, carboxymethylcellulose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, polyvinyl acetal diethylamino acetate, polyvinyl pyrrolidone, gelatin, medium chain fatty acid triglycerides, polyoxyethylene hydrogenated castor oil 60, white sugar, carboxymethyl cellulose, corn starch, inorganic salts, etc.

[0171] The types of cancers treated and diagnosed by the present invention are not particularly limited, and are generally cancers expressing hROR1 protein, preferably chronic lymphocytic leukemia, acute lymphocytic leukemia, chronic mantle cell lymphoma, sarcoma, ovarian cancer, renal cell carcinoma, head and neck cancer, breast cancer, lung cancer, malignant mesothelioma, colon cancer, neuroblastoma or melanoma.

[0172] Furthermore, the pharmaceutical compositions of the present invention may be formulated with multiple antibodies as needed. For example, by creating a mixture of multiple anti-hROR1 antibodies, cytotoxicity against hROR1-expressing cells may be enhanced. Alternatively, in addition to anti-hROR1 antibodies, the therapeutic effect may be enhanced by combining antibodies that recognize other tumor-associated antigens.

[0173] Unless otherwise specified, the CDR sequences in the present invention are defined by the Kabat definition scheme, and the related amino acid numbering is determined by the Kabat numbering scheme. It should be understood that when different definition schemes are used to define CDRs, the predicted CDR region sequences may only partially overlap, or be shortened or lengthened.

[0174] The present invention is further described below with reference to examples.

[0175] Example 1. Cell lines

[0176] Human ovarian cancer cell line PA-1, human triple-negative breast cancer cell lines MDA-MB-231 and MCF-7, and human sarcoma cell line Saos-2 were all purchased from ATCC.

[0177] The MDA-MB-231 cell line was grown in DMEM (Thermo Scientific; Logan, UT) supplemented with 10% (v / v) heat-inactivated FBS (Thermo Scientific; Logan, UT).

[0178] The Saos-2 cell line was grown in RPMI 1640 (Thermo Scientific; Logan, UT) supplemented with 10% (v / v) heat-inactivated FBS (Thermo Scientific; Logan, UT).

[0179] PA-1 and MCF-7 cell lines were grown in MEM (Thermo Scientific; Logan, UT) supplemented with 10% (v / v) heat-inactivated FBS (Thermo Scientific; Logan, UT), 1% (v / v) nonessential amino acids, and 1 mM sodium pyruvate to support adherent culture.

[0180] Each culture medium was supplemented with 100 U / mL penicillin and 100 mg / mL streptomycin (Sigma Aldrich).

[0181] Example 2. Mouse immunization and antibody screening

[0182] Immunogen Preparation and Mouse Immunization: Human ROR1(30-403)-His was used as the immunogen to generate anti-hROR1 monoclonal antibodies. Fifteen mice (5 BALB / c mice, 5 C57bl / 6 mice, and 5 A / J mice) were immunized subcutaneously with 50 μg of human ROR1(30-403)-His protein emulsified in complete Freund's adjuvant for the first immunization. Two weeks later, a second immunization was performed. Following the first immunization, mice were immunized three times with 25 μg of human ROR1(30-403)-His protein emulsified in incomplete Freund's adjuvant, alternating between intraperitoneal and subcutaneous injections at two-week intervals. Seven days after the fourth immunization, blood was collected from the tail of the mice for antigen-binding assay.

[0183] Antibody screening: BALB / c mice with high serum titers were selected from a pool of 15 mice for cell fusion. Splenocytes from these mice were electroporated with SP2 / 0 cells at a ratio of 20:1. Seven to 10 days after fusion, hybridoma supernatants were assayed for specific antibodies using indirect ELISA and FACS. Positive clones were selected for subcloning. After two subcloning steps, monoclonal cell lines, or hybridoma cell lines, were obtained. The positive hybridoma cell lines screened were 7F6D10, 33B10G8, 21A9A4, 84E3F11, and 94F8B4, respectively. Isotype identification was performed using the SBA Clonotyping System-HRP kit, and all selected antibodies were IgG1 kappa.

[0184] The amino acid sequences of the variable immunoglobulin heavy and light chains of the murine anti-hROR1 mAb are shown in FIG2 .

[0185] Using the framework regions (FRs) and complementarity determining regions (CDRs) defined by Kabat, the figure shows the heavy chain variable domain sequences (SEQ ID NOs: 1, 5, 9, 13, 17, respectively) and light chain variable domain sequences (SEQ ID NOs: 21, 25, 29, 33, 37, respectively) of five antibodies named 7F6D10, 33B10G8, 21A9A4, 84E3F11, and 94F8B4.

[0186] Example 3. Expression and purification of chimeric mouse / human IgG antibodies

[0187] The variable region coding region of the antibody was prepared by whole-genome synthesis using MHSSALLCCLVLLTGVRA as a leader signal peptide. The region was then assembled with the human IgH-γ1 and IgL-κ coding regions via NotI / XbaI restriction sites into the expression vector pcDNA3.4. This vector, which features a CMV promoter to enhance high-level expression of various genes in mammalian cells, also contains an ampicillin resistance gene for selective markers. CHO-K1 cells were selected as the host for antibody expression. The cells were passaged three times under appropriate conditions (120 rpm, 8% CO₂, 37°C). The cells were harvested and mixed with electroporation buffer. The plasmid was then added and mixed thoroughly, then transferred to an electroporation tube. The pcDNA3.4 expression vector was transfected into the CHO-K1 cells using an electroporator. After 24 hours of incubation at 37°C, 270 rpm, and 8% CO₂, the cells were supplemented with feed / sodium butyrate / dual antibiotics and incubated for 3-7 days. The harvested supernatant was filtered (0.22 μm) to remove cells and used for subsequent purification. The treated supernatant was purified using a Protein A affinity chromatography column, followed by elution with citrate buffer (pH 3.4). The eluate was placed in a dialysis bag for buffer exchange, ultimately yielding chimeric mouse / human IgG1 antibodies 7F6D10, 33B10G8, 21A9A4, 84E3F11, and 94F8B4. Their concentration and quantity were determined by reading the absorbance at A280 nM using a NanoDrop instrument. Purity was assessed by SDS-PAGE and SEC-HPLC, revealing a purity of >95%.

[0188] The following table lists the mouse / human IgG1 chimeric antibodies used in the subsequent examples, including their concentrations and dilutions.

[0189] Example 4. Detection of Antibody Binding Activity

[0190] ELISA: For ELISA, each well of a 96-well 3590 plate (Corning, NY) was coated with 100 μL of coating buffer (0.015 M Na₂CO₃, 0.035 M NaHCO₃, pH 9.5) containing 50 ng of antigen protein at 4°C overnight. After blocking with 150 μL of PBS buffer containing 4% (w / v) nonfat dry milk per well at 37°C for 1 hour, the supernatant was discarded and the wells were drained on a clean paper towel. Then, a 4-fold serial dilution of the test antibody (7F6D10, 33B10G8, 21A9A4, 84E3F11, or 94F8B4) was added to each well at 37°C as the primary antibody. After incubation for 1 hour, the wells were washed three times with 1% PBST and the supernatant was discarded. Then add 100uL of PBS buffer per well containing 1.25ng / mL horseradish peroxidase (HRP)-conjugated goat anti-human IgG Fc (Invitrogen, California, CA) and 4% (w / v) skim milk powder and incubate at 37°C for 45 minutes. After washing three times with 1% PBST, the color reaction was performed using TMB color development solution (Beyotime, Shanghai, CN) according to the manufacturer's instructions, incubated at room temperature in the dark for 15 minutes until the color developed to the expected depth, and then used TMB color development stop solution. The absorbance was measured at 450nm using a SpectraMax i3X microplate reader (Molecular Devices; Sunnyvale, CA). To determine the epitope range, hROR1_Ig-like, hROR1_Frizzled or hROR1_Kringle protein was directly coated and then incubated with the antibody to be tested and detected in the same way.

[0191] Flow cytometry: 40,000 cells were seeded per well in a 96-well round-bottom plate. A serial dilution of the primary antibody (starting at 100 nM and diluted four-fold to 0.006 nM) was added and incubated at 4°C for 1 hour. A blank control was incubated with the secondary antibody alone, without the primary antibody. After incubation, the cells were centrifuged and the supernatant discarded. The cells were washed twice with 200 μL / well of ice-cold 1% (v / v) FBS in PBS. A FITC-conjugated goat anti-human IgG polyclonal antibody was then incubated at 4°C for 1 hour, followed by repeated washing steps. The supernatant was discarded and the cells were resuspended in 100 μL / well of 1% FBS in PBS. Cell-bound staining was analyzed using a flow cytometer (Agilent), and data were analyzed using GraphPad 9.5.1.

[0192] Figure 3 shows the measured binding activity of chimeric mouse / human anti-hROR1 antibodies to the commercial mature hROR1 full-length extracellular region, three different domains of the hROR1 extracellular region, and the mature hROR2 full-length extracellular region. Each chimeric mouse / human Fab was analyzed by ELISA for binding to the mature hROR1 full-length extracellular region (hROR1_ECD), human hROR1 Ig-like domain (hROR1_Ig-like), hROR1 Frizzled domain (hROR1_Frizzled), hROR1 Kringle domain (hROR1_Kringle), and mature hROR2 full-length extracellular region (hROR2_ECD). These commercial antigens have been validated for use in ELISA experiments with anti-human ROR1 or / ROR2 antibodies to detect antibody binding activity. His-tagged hROR1_ECD, hROR1_Ig-like, hROR1_Frizzled, hROR1_Frizzled, or hROR2_ECD were captured by chimeric mouse / human anti-hROR1 antibodies immobilized on the plate and then detected using goat anti-human HRP antibodies as secondary antibodies.

[0193] FIG4 shows FACS cell staining of Ab-1 to Ab-5 on human triple-negative breast cancer cells MDA-MB-231.

[0194] FIG5 shows the binding activity of selected chimeric mouse / human IgG to endogenous hROR1 expressed on human breast cancer cells MDA-MB-231 as determined by fluorescence activated cell sorting (FACS).

[0195] Example 5. Detection of anti-endocytic activity using pHrodoiFLgreen

[0196] PA-1 and MDA-MB-231 cells were cultured overnight in a constant temperature incubator (37°C, 5% CO2). The selected antibodies Ab-1 to Ab-5 were labeled with pHrodo iFL Green human IgG reagent, and the antibody-pHrodo iFL Green human IgG conjugates were incubated with human ovarian cancer cells PA-1 and human breast cancer cells MDA-MB-231 for 24 hours. The highest concentration of the antibody was set to 10 μg / ml and a 4-fold serial dilution was performed. After incubation, the cells were washed with PBS and resuspended in culture medium. The fluorescence intensity excited by pHrodo iFL Green entering the cells was measured on a NovoCyte flow cytometer to analyze the endocytic activity of the antibody.

[0197] Figure 6 shows the internalization of selected chimeric murine / human IgGs in human ovarian cancer cells PA-1 and human breast cancer cells MDA-MB-231, which express endogenous hROR1. Abs 1 to 5 are hROR1-specific mAbs, along with control antibodies UC961 and C2E3. (A) Endocytic activity of selected antibodies in PA-1 cells. (B) Endocytic activity of selected antibodies in MDA-MB-231 cells.

[0198] Example 6. Expression and characterization of purified, recombinant anti-hROR1 bispecific antibodies

[0199] Four bispecific antibodies were constructed using chimeric human IgGs 7F6D10 and 84E3F11. Expression and purification of the bispecific antibodies were performed as described in Example 3. The variable region coding regions of the bispecific antibodies were cloned, assembled into a pcDNA expression vector, and transfected into CHO-K1 cells for eukaryotic expression and purification. The resulting purified antibodies were designated Ab-6 through Ab-9.

[0200] FIG7 shows schematic diagrams of the structures of different bispecific antibodies based on selected chimeric mouse / human IgG.

[0201] The selected bispecific antibodies 84E3F11-7F6D10 and 7F6D10-84E3F11 are in DVD-Ig format; the selected bispecific antibody 84E3F11-7F6D10-VH-VL is in IgG-scFv format; and the selected bispecific antibody 84E3F11-7F6D10(cross) is in CrossMab format, as shown in Figure 7. (A) is a schematic structural diagram of the selected bispecific antibodies, and (B) is the sequence of the selected bispecific antibodies.

[0202] Table 3 lists the final concentrations and buffers of selected mouse / human chimeric bispecific antibodies.

[0203] FIG8 shows the binding activity of selected bispecific antibodies to endogenous hROR1 expressed on human breast cancer cells MDA-MB-231.

[0204] Example 7. Expression and characterization of purified, recombinant chimeric antibody mutants or humanized anti-hROR1 antibodies

[0205] The expression and purification of chimeric antibody mutants or humanized antibodies were carried out as described in Example 3.

[0206] Table 4 Chimeric antibody mutants or humanized antibodies, including their concentrations and dilutions.

[0207] FIG9 shows the ELISA binding activity of chimeric antibody mutants or humanized anti-hROR1 antibodies to the full-length extracellular region of mature hROR1.

[0208] Example 8. Generation of ADC-1 to 56 by coupling using antibody interchain disulfide bonds and / or cysteine ​​mutation sites

[0209] The following ADCs-1 to 23 were prepared by coupling 1 to 20 anti-tumor toxin molecules through the interchain disulfide bond sites of the antibody:

[0210] FIG10(A) illustrates the overall method for preparing antibody-drug conjugates using cysteine ​​and maleimide linkers corresponding to antibody interchain disulfide bond sites. The specific conjugation process for synthesizing ADCs 1 to 23 is as follows: Add 2 mg of antibody to a 0.5 ml centrifuge tube. Dilute the antibody to 5 mg / ml with 30 mM His-HAC (pH 5.5) buffer. Add 100 mM EDTA aqueous solution to a final concentration of 5 mM and vortex to mix. Add 2 mg / ml TCEP aqueous solution at a 3:1 TCEP to antibody molar ratio, vortex to mix, and incubate at 20°C in a thermomixer for 1.5 hours. Add 10 mg / ml linker-toxin DMSO solution at a 12:1 compound to antibody molar ratio, and replenish DMSO to 20% of the final reaction volume. Vortex to mix, and incubate at 20°C in a thermomixer for 1.5 hours. After the coupling is complete, 300 mg / mL dextran-coated activated carbon (Sigma) is used to remove free small molecules. Finally, the ADC storage buffer is replaced with 50 mM PBS (pH 7.2) using an ultrafiltration tube and stored at -80°C until use.

[0211] 10(B) illustrates the overall method for preparing antibody-drug conjugates using cysteine ​​and ene linkers corresponding to interchain disulfide bond sites of antibodies. Specifically, the conjugation process for synthesizing ADC-24 is as follows: Add 2 mg of antibody to a 0.5 ml centrifuge tube. Dilute the antibody to 10 mg / ml with 25 mM Na2B4O7, 25 mM NaCl, and 1 mM DTPA (pH 7.4) buffer. Add a volume of TCEP or DTT aqueous solution 2 to 15 times the molarity of the antibody, vortex to mix, and incubate at 20°C in a thermomixer for 2 to 24 hours. Add a volume of toxin-linker solution 4 to 24 times the molarity of the antibody. Vortex to mix, and incubate at 20°C in a thermomixer for 0.5 to 24 hours. After conjugation, stop the reaction and purify the ADC.

[0212] 10(A) and 10(C) illustrate the overall preparation method of antibody-drug conjugates, wherein 1-20 anti-tumor toxin molecules are conjugated via antibody interchain disulfide bonds and / or cysteine ​​mutation sites to prepare the following ADC-25-56.

[0213] To a 0.5ml centrifuge tube, add 2mg of antibody. Dilute the antibody to 5mg / ml with 30mM His-HAC (pH 5.5) buffer. Add 100mM EDTA to a final concentration of 5mM and vortex to mix. Add 2mg / ml TCEP in water at a 3:1 TCEP to antibody molar ratio, vortex to mix, and incubate at 20°C in a thermomixer for 1.5 hours. Alternatively, use a desalting column to exchange the antibody buffer with 2mM EDTA and 100mM Tris-HCl (pH 8.0). To a 1.5ml centrifuge tube, add 1mg of antibody. Add 100mM DTT in water at a DTT to antibody molar ratio of 20:1-100:1. Mix by pipetting, and incubate overnight at 22°C in a thermomixer. Add 10mg / ml linker-toxin DMSO at a 12:1 compound to antibody molar ratio, and make up DMSO to 20% of the final reaction volume. After vortexing and mixing, incubate in a thermomixer at 20°C for 1.5 hours. After coupling, remove free small molecules using 300 mg / mL dextran-coated activated charcoal (Sigma). Finally, replace the ADC storage buffer with 50 mM PBS (pH 7.2) using an ultrafiltration tube and freeze at -80°C until needed.

[0214] Alternatively, use a desalting column to exchange the antibody buffer with 2mM EDTA, 100mM Tris-HCl (pH 8.0). In a 1.5ml centrifuge tube, add 1mg of antibody and add 100mM DTT at a molar ratio of 100:1. Pipette mix thoroughly and incubate overnight at 22°C in a thermomixer. Use a desalting column to exchange the antibody buffer with 2mM EDTA, 150mM NaCl, 50mM Tris-HCl (pH 7.5). Add 100mM DHAADMA at a molar ratio of 20:1 DHAA to antibody. Pipette mix thoroughly and incubate at 22°C in a thermomixer for 2 hours. Remove the DHAA using a desalting column and exchange the antibody buffer with 150mM NaCl, 50mM Tris-HCl (pH 7.5). Add a 10 mg / ml linker-toxin DMA solution at a compound-to-antibody molar ratio of 6:1, and replenish DMA to 10% of the final reaction volume. Mix thoroughly by vortexing and incubate at 20°C in a thermomixer for 4 hours. After conjugation, remove free small molecules using a desalting column. Adjust the ADC storage buffer to 50 mM His-HAC (pH 5.5) and store frozen at -80°C until ready for use.

[0215] Example 9. In vitro cytotoxicity assay of ADC based on anti-ROR1 antibody

[0216] 1.5×10 3 Cells were seeded in a 96-well plate (excluding the edge wells filled with PBS). The cells were cultured in 80 μL of DMEM supplemented with 10% FBS (v / v), 100 U / mL penicillin and 100 mg / mL streptomycin, and cultured overnight in a humidified incubator at 37°C and 5% CO2. After incubation in a constant temperature incubator for one day, the diluted solution (20 μl per well) was added to each well to make the final ADC concentration range from 0.01 nM to 1000 nM. After incubation with the cells (37°C, 5% CO2) for five days, the 96-well plate was removed from the incubator and equilibrated to room temperature. About 30 minutes later, 40 μL of (Promega, G7572). The plate was shaken at 450 rpm for 5 minutes and allowed to equilibrate for 10 minutes without shaking. Fluorescence was then measured using a SpectraMax i3X microplate reader. Luminescence versus ADC concentration (nM) was fitted using Graphpad Prism software. IC50 values ​​were determined using the built-in "log (Inhibitor) vs. Response - Variable Slope (4 Parameters)" function in Prism software.

[0217] Figure 11 (AC) shows the cytotoxicity of selected anti-ROR1 ADCs on human triple-negative breast cancer cells MDA-MB-231 at concentrations ranging from 0.01 to 1000 nM. (D) shows the cytotoxicity of selected anti-ROR1 ADCs on human sarcoma cells Saos2 at concentrations ranging from 0.01 to 1000 nM. (E) shows the cytotoxicity of selected anti-ROR1 ADCs on sarcoma cells SK-UT-1 at concentrations ranging from 0.01 to 1000 nM.

[0218] Example 10. Evaluation of the in vivo efficacy of anti-hROR1 ADC in an ovarian cancer model established with hROR1-positive human ovarian cancer PA-1 cells.

[0219] On day 0 of the study, mice aged 8-12 weeks, weighing at least 20 g each, were inoculated with PA-1 ovarian cancer tumor cells (5 × 10 6 cells / animal, 1:1 with Matrigel in 100 μL PBS). On day 21 after transfer, ADC formulated in PBS was administered (iv) to a group of 6 mice at 3 mg / kg. PBS served as a negative vehicle control. All treatment groups were injected into the tail vein at a volume of 5 L / kg once a week for three weeks. Tumor volume was measured to determine whether tumor growth was inhibited, delayed, or cured. Tumor size was measured twice a week with a caliper, and the average tumor volume of mice in each group was plotted over time. Volume is expressed in mm 3 The formula is as follows: V = 0.5a × b 2 , where a and b are the long and short diameters of the tumor, respectively. The use and welfare of experimental animals will comply with the rules of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) International.

[0220] Figure 12 shows the anti-tumor efficacy of ADC-41, DAR4, in an ovarian cancer xenograft model in female balb / c nude mice injected with hROR1 -positive PA-1 cells.

[0221] The embodiments of the present invention are only used to illustrate the present invention and do not limit the scope of the claims. Other substantially equivalent alternatives that can be thought of by those skilled in the art are all within the scope of protection of the present invention.

Claims

1. An isolated antigen binding protein capable of binding hROR1, characterized in that Contains any one of a~o: a. having a first heavy chain variable region, comprising HCDR1 of the amino acid sequence TYAMS, HCDR2 of the amino acid sequence SISSGGSTYYPDSVKG, and HCDR3 of the amino acid sequence YSLMVEAHWYFDV, b. having a second heavy chain variable region, comprising HCDR1 having an amino acid sequence of SYAMS, HCDR2 having an amino acid sequence of SISSGGSTYYPDSVKG, and HCDR3 having an amino acid sequence of GYSNYVDWYFDV, c. having a third heavy chain variable region, comprising HCDR1 with an amino acid sequence of DYTMH, HCDR2 with an amino acid sequence of GIDPNYGGTNYNEKFKD, and HCDR3 with an amino acid sequence of DDGYYEDYFDY, d. having a fourth heavy chain variable region, comprising HCDR1 of the amino acid sequence SYWIE, HCDR2 of the amino acid sequence EILPGSGNTQNNEKFKG, and HCDR3 of the amino acid sequence EGRRSHFFDY, e. having a fifth heavy chain variable region, comprising HCDR1 of the amino acid sequence RYAMS, HCDR2 of the amino acid sequence SISSGGSTYYPDSVKG, and HCDR3 of the amino acid sequence GYYGNNDWYFDV, f. having a first light chain variable region, comprising LCDR1 with an amino acid sequence of KASQDINSYLS, LCDR2 with an amino acid sequence of RANRLVD, and LCDR3 with an amino acid sequence of LQYDEFPYT, g. having a second light chain variable region, comprising LCDR1 with an amino acid sequence of KATQDINSYLS, LCDR2 with an amino acid sequence of RPNRLVD, and LCDR3 with an amino acid sequence of LQYDEFPYT, h. having a third light chain variable region, comprising LCDR1 with an amino acid sequence of HASQGISSNIG, LCDR2 with an amino acid sequence of HGTNLED, and LCDR3 with an amino acid sequence of VQYAQFPYT, i. having a fourth light chain variable region, comprising LCDR1 having an amino acid sequence of KSSQSLLNSSNQKNYLA, LCDR2 having an amino acid sequence of FASTRES, and LCDR3 having an amino acid sequence of QQHYSSPWT, j. having a fifth light chain variable region, comprising LCDR1 with an amino acid sequence of KASQDINSYLS, LCDR2 with an amino acid sequence of RANSLVD, and LCDR3 with an amino acid sequence of LQFDEFPYT, k. having the first heavy chain variable region described in item a and the first light chain variable region described in item f, l. having the second heavy chain variable region described in item b and the second light chain variable region described in item g, m. having the third heavy chain variable region described in item c and the third light chain variable region described in item h, n. having the fourth heavy chain variable region described in item d and the fourth light chain variable region described in item i, o. having the fifth heavy chain variable region described in item e and the fifth light chain variable region described in item j.

2. The antigen-binding protein according to claim 1, characterized in that It has a framework region of mouse origin or a framework region of human origin.

3. The antigen-binding protein according to claim 2, characterized in that The framework region is an IgG framework region.

4. The antigen-binding protein according to claim 2, characterized in that The human framework region has a back mutation at one or more sites relative to the mouse framework region.

5. The antigen-binding protein according to claim 1, characterized in that It also has a constant region.

6. The antigen-binding protein according to claim 5, characterized in that The heavy chain constant region of any one of a to e, k to o contains one or more mutations of C220S, A121C, V205C, K149C, D265C, S239C, A330C, and S442C.

7. The antigen-binding protein according to claim 1, characterized in that The antigen binding protein includes an antibody or an antigen binding fragment thereof.

8. The antigen-binding protein according to claim 1, characterized in that The heavy chain variable region has a S62Q, S62A, S62N, S62E, S62V, S62Y, S62F or S62K mutation.

9. The antigen-binding protein according to claim 1, characterized in that The light chain variable region has a G57A, G57S, G57N or G57L mutation.

10. The antigen binding protein according to claim 1, characterized in that The light chain variable region has a D56E, D56Q, D56T or D56Y mutation.

11. The antigen binding protein according to claim 1, characterized in that The light chain variable region has S31A, S31Q, S31L, S31V, S31E, S31Y, S31F or S31K mutation.

12. The antigen binding protein according to claim 1, characterized in that The light chain variable region has T57A, T57Q, T57L, T57V, T57E, T57Y, T57F or T57K mutations.

13. The antigen binding protein according to claim 1, characterized in that The light chain variable region has S27A, S27Q, S27L, S27V, S27E, S27Y, S27F, and S27K mutations.

14. The antigen binding protein according to claim 1, characterized in that A heavy chain having an amino acid sequence as shown in any one of SEQ ID No.53, 54, 55, 56, 57, 58, 59, 60, 62, 63, 65, 73, 75, 78, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 90, 91, 92, 93, 134 or 135, and a light chain having an amino acid sequence as shown in any one of SEQ ID No.64, 66, 67, 68, 70, 71, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 105, 106, 108, 109, 110, 112, 113, 114, 115, 116, 117, 119, 120, 121, 122 or 123.

15. The antigen binding protein according to claim 1, characterized in that Any one selected from antibodies Ab-1 to Ab-5, wherein Ab-1 has a heavy chain having an amino acid sequence as shown in SEQ ID NO.124, and a light chain as shown in SEQ ID NO.129; Ab-2 has a heavy chain having an amino acid sequence as shown in SEQ ID NO.125, and a light chain as shown in SEQ ID No.130; Ab-3 has a heavy chain having an amino acid sequence as shown in SEQ ID NO.126, and a light chain as shown in SEQ ID No.131; Ab-4 has a heavy chain having an amino acid sequence as shown in SEQ ID NO.127, and a light chain as shown in SEQ ID NO.132; Ab-5 has a heavy chain having an amino acid sequence as shown in SEQ ID NO.128, and a light chain having an amino acid sequence as shown in SEQ ID NO.

133.

16. An isolated bispecific antigen binding protein capable of binding hROR1, characterized in that have: A first antigen-binding fragment that binds to the Ig-like domain in hROR1, wherein the first antigen-binding fragment has a first heavy chain variable region and a first light chain variable region, wherein The first heavy chain variable region comprises a HCDR1 with an amino acid sequence of TYAMS, a HCDR2 with an amino acid sequence of SISSGGSTYYPDSVKG, and a HCDR3 with an amino acid sequence of YSLMVEAHWYFDV, The first light chain variable region comprises LCDR1 with an amino acid sequence of KASQDINSYLS, LCDR2 with an amino acid sequence of RANRLVD, and LCDR3 with an amino acid sequence of LQYDEFPYT, A second antigen-binding fragment that binds to the Kringle domain in hROR1, wherein the second antigen-binding fragment has a fourth heavy chain variable region and a fourth light chain variable region, wherein The fourth heavy chain variable region comprises a HCDR1 with an amino acid sequence of SYWIE, a HCDR2 with an amino acid sequence of EILPGSGNTQNNEKFKG, and a HCDR3 with an amino acid sequence of EGRRSHFFDY. The fourth light chain variable region contains LCDR1 with an amino acid sequence of KSSQSLLNSSNQKNYLA, LCDR2 with an amino acid sequence of FASTRES, and LCDR3 with an amino acid sequence of QQHYSSPWT.

17. The bispecific antigen-binding protein of claim 16, characterized in that It has a framework region of mouse origin or a framework region of human origin.

18. The bispecific antigen-binding protein of claim 17, characterized in that The framework region is an IgG framework region.

19. The bispecific antigen-binding protein of claim 17, characterized in that The human framework region has a back mutation at one or more sites relative to the mouse framework region.

20. The bispecific antigen-binding protein of claim 16, wherein It also has a constant region.

21. The bispecific antigen-binding protein of claim 20, characterized in that The heavy chain constant region of the first antigen-binding fragment contains one or more mutations among C220S, A121C, V205C, K149C, D265C, S239C, A330C, and S442C.

22. The bispecific antigen-binding protein of claim 20, characterized in that The heavy chain constant region of the second antigen-binding fragment contains one or more mutations of C220S, A121C, V205C, K149C, D265C, S239C, A330C, and S442C.

23. The bispecific antigen-binding protein of claim 16, characterized in that The bispecific antigen-binding protein is IgG-like or non-IgG-like.

24. The bispecific antigen binding protein of claim 23, characterized in that The IgG-like antigen binding protein is selected from DVD-Ig bispecific antigen binding protein, IgG-scFv bispecific antigen binding protein or CrossMAb bispecific antigen binding protein.

25. The bispecific antigen-binding protein of claim 16, characterized in that With any of p, q, r, s: p. a first heavy chain having an amino acid sequence as shown in 61, a second heavy chain having an amino acid sequence as shown in 140, a first light chain having an amino acid sequence as shown in 69, and a second light chain having an amino acid sequence as shown in 141; q. a first heavy chain having an amino acid sequence as shown in 72, a second heavy chain having an amino acid sequence as shown in 137, a first light chain having an amino acid sequence as shown in 69, and a second light chain having an amino acid sequence as shown in 141; r. a first heavy chain having an amino acid sequence as shown in 89, a second heavy chain having an amino acid sequence as shown in 138, a first light chain having an amino acid sequence as shown in 69, and a second light chain having an amino acid sequence as shown in 139; s. A first heavy chain having an amino acid sequence as shown in 136, and a second heavy chain having an amino acid sequence as shown in 142, a first light chain having an amino acid sequence as shown in 69, and a second light chain having an amino acid sequence as shown in 139.

26. The bispecific antigen-binding protein of claim 16, characterized in that Any one selected from antibodies Ab-6 to Ab-9, wherein Ab-6 is in the form of DVD-Ig, having a heavy chain with an amino acid sequence as shown in SEQ ID NO.45, and a light chain as shown in SEQ ID No.49; Ab-7 is in the form of IgG-scFv, having a heavy chain with an amino acid sequence as shown in SEQ ID No. 46, and a light chain as shown in SEQ ID No. 50; Ab-8 is in the form of crossmab, having a first heavy chain with an amino acid sequence as shown in SEQ ID NO.47, and a first light chain with an amino acid sequence as shown in SEQ ID NO.67; a second heavy chain with an amino acid sequence as shown in SEQ ID NO.51, and a second light chain with an amino acid sequence as shown in SEQ ID No.69; The Ab-9 format is a DVD-Ig having a heavy chain with an amino acid sequence as shown in SEQ ID No.48, and a light chain with an amino acid sequence as shown in SEQ ID No.

52.

27. A nucleic acid molecule characterized in that Used to encode the antigen binding protein according to any one of claims 1 to 15 or used to encode the bispecific antigen binding protein according to any one of claims 16 to 26.

28. A carrier, characterized in that Comprising the nucleic acid molecule of claim 27.

29. A cell comprising the nucleic acid molecule of claim 27, and / or the vector of claim 28.

30. A drug molecule characterized in that It comprises the antigen binding protein according to any one of claims 1 to 16 or the bispecific antigen binding protein according to any one of claims 17 to 26.

31. The drug molecule according to claim 30, characterized in that The structure is shown in Formula I: Ab is the antigen binding protein, L is a linker containing one or more linkers, D is the therapeutic agent or detectable marker, and n is an integer selected from 1-20.

32. The drug molecule according to any one of claims 31, characterized in that n is selected from integers of 2-8.

33. The drug molecule according to claim 31, characterized in that Also included are therapeutic agents or detectable markers, wherein the therapeutic agent is selected from a cytotoxic agent, a cytostatic agent, a radioisotope, an anti-angiogenic agent, an immunomodulator, or a liposome.

34. The drug molecule according to claim 33, characterized in that The cytotoxic agent is selected from one or more of maytansine alkaloids, auristatins, eribulin, taxanes, calicheamicin, cemadotine, pyrrolobenzodiazepines, anthracyclines, camptothecin derivatives, α-amanitin and its derivatives, trabectedin and its derivatives, rubectedin and its derivatives.

35. The drug molecule according to claim 31, characterized in that The linker is selected from one or more of an oligopeptide linker, a hydrazine linker, a thiourea linker, a triggered self-degradation linker, a succinimidyl trans-4-(maleimidomethyl)cyclohexane-1-carboxylate linker, a maleimide linker, a disulfide linker, a thioether linker, and an olefin linker.

36. The drug molecule according to claim 31, characterized in that Any one selected from ADC1 to 56:

37. Use of the antigen binding protein of any one of claims 1 to 15, the bispecific antigen binding protein of any one of claims 16 to 26, the nucleic acid molecule of claim 27, the vector of claim 28, the cell of claim 29, and / or the drug molecule of any one of claims 30 to 35 in the preparation of a drug, wherein the drug is used for diagnosing, preventing and / or treating hROR1-related diseases and / or conditions.

38. The use according to claim 37, characterized in that The diseases and / or conditions include tumors.

39. The use according to claim 38, characterized in that The tumor is chronic lymphocytic leukemia, acute lymphocytic leukemia, chronic mantle cell lymphoma, sarcoma, ovarian cancer, renal cell carcinoma, head and neck cancer, breast cancer, lung cancer, malignant mesothelioma, colon cancer, neuroblastoma or melanoma.

Citation Information

Patent Citations

  • ROR1 antibody compositions and related methods

    CN108848669A

  • ROR1 (receptor tyrosine kinase-like orphan receptor) monoclonal antibody, preparation method and application of ROR1 monoclonal antibody

    CN110590951A

  • ROR1 antibody or antigen binding fragment thereof

    CN114539411A

  • ROR1 binding proteins and uses thereof

    CN115043942A

  • Antigen binding proteins that bind ROR1

    WO2022217054A1